THA William Woodfin MD Multidisciplinary Conference - Update on CAR T-Cell Therapy for Myeloma
Target Audience
This online educational enduring material is designed for physicians and nurses. Its purpose is to address the need to improve projected and future patient outcomes by investigating opportunities for improvement and physician growth.
Learning Objectives
At the end of this online enduring material, participants should be able to:
- Identify FDA approved CAR T-cell therapies for myeloma
- Review the main side effects of CAR T-cell therapy
- Describe the targets of CAR T-cell therapy for myeloma vs lymphoma
Available Credit
- 0.75 AMA PRA Category 1 Credit™
In support of improving patient care, Texas Health Resources is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Texas Health Resources designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 0.75 Attendance
- 0.75 Nursing Contact Hour(s)In support of improving patient care, Texas Health Resources is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.